Bristol-Myers Squibb Company
OX-40 AGONIST, PD-1 PATHWAY INHIBITOR AND CTLA-4 INHIBITOR COMBINATION FOR USE IN A METHOD OF TREATING A CANCER OR A SOLID TUMOR

Abstract:

Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an OX40 agonist, a PD-1 pathway inhibitor, and a CTLA-4 inhibitor.